Search
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors. … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Bromhexine
go.drugbank.com/drugs/DB09019ApprovedInvestigationalIt was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries. … It is derived from the Adhatoda vasica plant and aids in the clearance of excess mucus, improving breathing and reducing cough.
Synonyms: N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine, 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamineMixtures: GLICERTOX N FDonepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalDonepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia. … [A182411] Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage
Products: DONEPEZIL WIN MEDICALarotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalan important role in tumor cell growth and survival. … of cell growth in tumors that overexpress Trk.
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigationalDifelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes
Zenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [A264833,A264843] Zenocutuzumab is also capable of promoting antibody-dependent cellular cytotoxicity in cancer cells.
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. … Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America.
Categories: Compounds used in a research, industrial, or household settingErdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalCo-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier … It is a _thiol_ derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawna 68% reduction in the risk of death were observed. … [A262829] Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells